Curasight Reports Encouraging Phase 1 Data for uTREAT® in Glioblastoma, Supporting Continued Development
核心洞察
Preliminary Phase 1 data show uTREAT® (搜索) achieves high tumor uptake and retention with a therapeutically relevant radiation dose while sparing healthy organs in glioblastoma (搜索) patients.
The super-selective intra-arterial cerebral injection (super-SIACI) with mannitol-mediated blood-brain barrier opening was demonstrated to be feasible and safe.
Curasight's CEO Ulrich Krasilnikoff expressed confidence in advancing the program, calling the approach a potentially game-changing radioligand therapy for glioblastoma (搜索).
Curasight A/S has announced an encouraging preliminary readout from its Phase 1 clinical trial evaluating uTREAT® (搜索) in patients with glioblastoma (搜索), the most aggressive form of brain cancer. The data, reported on June 8, 2026, support the feasibility and safety of the novel administration approach and demonstrate the ability to deliver therapeutically relevant radiation doses directly to tumors while avoiding dose limits for healthy organs.
The preliminary findings mark an important step for Curasight's uPAR (搜索) theranostic platform, which combines the diagnostic imaging agent uTRACE® (搜索) with the targeted radiopharmaceutical therapy uTREAT® (搜索) — both directed against the urokinase-type plasminogen activator receptor (uPAR).
Mode of Administration Demonstrates Feasibility and Safety
The Phase 1 trial employs a distinctive delivery method: super-selective intra-arterial cerebral injection (super-SIACI), in which uTREAT® (搜索) is administered via catheter directly into the vessels feeding the tumor. To enhance tumor targeting, the blood-brain barrier is transiently opened using the osmotic compound mannitol. According to the preliminary readout, this mode of administration was found to be feasible and safe.
The data further showed high uptake and retention of uTREAT® (搜索) in tumor tissue, with biodistribution and dosimetry results compatible with delivering a therapeutically relevant radiation dose to the tumor without reaching dose limits for healthy organs.
"The preliminary readout of our Phase 1 clinical trial with uTREAT® (搜索) in glioblastoma (搜索) is encouraging and supports the ability of our technology to safely deliver therapeutically relevant radiation doses to the tumor without reaching dose limits for healthy organs," said Curasight CEO Ulrich Krasilnikoff. "With these data, we are confident in moving forward with the Phase 1 trial and the development program for uTREAT®, with the ambition of developing a potentially game-changing radioligand therapy for patients with glioblastoma."
Trial Design and Patient Population
The ongoing Phase 1 trial investigates uTREAT® (搜索) as a new targeted radioligand therapy in patients with newly diagnosed, verified or suspected glioblastoma (搜索). The super-SIACI administration approach is specifically designed to achieve high binding of uTREAT® in tumors while minimizing radiation exposure to healthy organs — a critical consideration given the sensitivity of surrounding brain tissue.
The Glioblastoma (搜索) Treatment Landscape
Glioblastoma (搜索) and other high-grade gliomas (WHO grades 3 or 4) represent a significant unmet medical need. More than 30,000 patients are diagnosed annually with glioblastoma in the US and EU, out of approximately 65,000 total primary brain tumor diagnoses. Approximately 10% of primary brain tumor patients are children.
The prognosis for glioblastoma (搜索) remains dismal: approximately 50% of patients die within 14 months of diagnosis, and only 5% survive beyond five years. While external beam radiation is a cornerstone of current brain cancer therapy, uTREAT® (搜索) could potentially complement existing radiation strategies by offering more specific tumor tissue targeting, thereby reducing radiation exposure to healthy brain tissue.
Curasight's uPAR (搜索) Theranostic Platform
Curasight's broader ambition is to develop both uTRACE® (搜索) and uTREAT® (搜索) as an integrated theranostic approach for uPAR (搜索)-expressing cancers. uTRACE® is designed to deliver sensitive imaging for diagnosis, while uTREAT® provides a matched therapeutic solution — together enabling a more personalized strategy for cancer detection and treatment.